Captrust Financial Advisors Cyma Bay Therapeutics, Inc. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $183,589 - $355,695	-14,536 Reduced 31.94%	30,973 $731,000
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $494,227 - $801,868	45,509 New	45,509 $678,000
Q2 2022 Aug 16, 2022	SELL	$1.72 - $3.39 $2,800 - $5,518	-1,628 Reduced 22.44%	5,628 $17,000
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $4,008 - $5,708	1,241 Added 20.63%	7,256 $25,000
Q1 2021 May 17, 2021	BUY	$4.23 - $6.55 $10,638 - $16,473	2,515 Added 71.86%	6,015 $27,000

Q3 2020 Nov 17, 2020	BUY	$3.32 - $7.24 $11,620 - $25,340	3,500 New	3,500 $25,000

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.